The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers.

被引：0
|
作者：
Kouta, H.
Kudoh, K.
Takano, M.
Kikuchi, R.
Kita, T.
Goto, T.
Furuya, K.
Kikuchi, Y.
机构：
[1] Ohki Mem Canc Ctr Women, Tokorozawa, Saitama, Japan
[2] Nishisaitama Chuo Natl Hosp, Tokorozawa, Saitama, Japan
[3] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[4] Nara Prefectural Nara Hosp, Nara, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study
    Zhang, Ying
    Yuan, Zhen
    Zhang, Guo-Nan
    Li, Qing-Shui
    Cui, Man-Hua
    Cheng, Wen-Jun
    Meng, Yuan-Guang
    Wu, Xiao-Hua
    Yue, Ying
    Wang, Li
    Hou, Jian-Qing
    Li, Chang-Zhong
    Qu, Peng-Peng
    Sun, Li-Xin
    Tao, Guang-Shi
    Li, Gui-Ling
    Chen, Ya-Qing
    Ren, Fang
    Cao, Dong-Yan
    Shen, Keng
    ONCOLOGIST, 2024,
  • [12] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer Reply
    Hamanishi, Junzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 523 - 524
  • [13] Weekly topotecan in patients with platinum-sensitive and platinum-resistant recurrent ovarian and peritoneal cancers.
    Tummala, M. K.
    Alagarsamy, S.
    Chyou, P.
    McGuire, W. P., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [14] Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox®)
    Khemapech, Nipon
    Oranratanaphan, S.
    Termrungruanglert, W.
    Lertkhachonsuk, R.
    Vasurattana, A.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (03) : 2131 - 2135
  • [15] Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer The APPROVE Randomized Clinical Trial
    Wang, Tiantian
    Tang, Jie
    Yang, Hongying
    Yin, Rutie
    Zhang, Jingru
    Zhou, Qi
    Liu, Ziling
    Cao, Lanqin
    Li, Li
    Huang, Yi
    Jiang, Kui
    Wang, Wei
    She, Fenglin
    Guan, Ni
    Hou, Zhiguo
    Li, Ning
    Wu, Lingying
    JAMA ONCOLOGY, 2022, 8 (08) : 1169 - 1176
  • [16] Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
    Pujade-Lauraine, E.
    Fujiwara, K.
    Ledermann, J. A.
    Oza, A. M.
    Kristeleit, R. S.
    Ray-Coquard, I. L.
    Richardson, G. E.
    Sessa, C.
    Yonemori, K.
    Banerjee, S.
    Leary, A.
    Tinker, A. V.
    Jung, K. H.
    Madry, R.
    Park, S. Y.
    Anderson, C. K.
    Zohren, F.
    Stewart, R.
    Wei, C.
    Dychter, S. S.
    Monk, B. J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 21 - 22
  • [17] Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer
    Witteveen, Petronella O.
    van der Mijn, Koen J. C.
    Los, Maartje
    Kronemeijer, Roelien H.
    Groenewegen, Gerard
    Voest, Emile E.
    NEOPLASIA, 2010, 12 (11): : 941 - 945
  • [18] A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
    Wu, Lingying
    Wang, Jing
    Wang, Li
    Lu, Weiguo
    Wang, Ke
    Lin, An
    Li, Ning
    Li, Li
    Su, Ning
    Xie, Shuang
    Jiang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [19] AVELUMAB COMBINED WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER: BIOMARKER ANALYSES FROM JAVELIN OVARIAN 200
    Pujade-Lauraine, E.
    Ledermann, J.
    Oza, A.
    Kristeleit, R.
    Ray-Coquard, I.
    Richardson, G.
    Sessa, C.
    Yonemori, K.
    Banerjee, S.
    Leary, A.
    Mu, X.
    Liu, Y.
    Ching, K.
    Deng, S.
    Smith, J. Perkins
    Donahue, A.
    Fujiwara, K.
    Monk, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A210 - A211
  • [20] Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
    Liu, Joyce F.
    Cannistra, Stephen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1287 - 1289
12345